NovaBridge Biosciences (NBP) Balance Sheet
NBP balance sheet, 2025
December 31, 2025 · U.S. dollars$37.2M assets = $4.2M liabilities + $33.0M equity
Both columns are drawn to the same scale: what NBP owns equals what it owes plus shareholders’ equity. Hover a block for its value.
NBP financial health
Descriptive bands, not a rating. Fiscal 2025.
NBP balance sheet trends, 2017–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $1.03B2017 | $37.2M2025 | −42.5%/yr | |
| Total liabilities | $1.33B2017 | $4.2M2025 | −61.6%/yr | |
| Shareholders’ equity | $410.5M2017 | $33.0M2025 | −34.3%/yr | |
| Cash & short-term investments | $574.2M2017 | $30.1M2025 | −38.8%/yr | |
| Total debt | $213.0M2017 | $438,4582025 | −64.3%/yr | |
| Net cash (debt) | $361.2M2017 | $29.7M2025 | −$331.5M | |
| Working capital | $496.4M2017 | $27.3M2025 | −$469.2M | |
| Book value per share | $7.062017 | $0.792025 | −30.5%/yr | |
| Current ratio | 3.542017 | 8.092025 | +4.54 | |
| Debt / equity | 0.522017 | 0.012025 | −0.51 | |
| Shares outstanding | 58.2M2017 | 41.6M2025 | −5.4%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
NBP assets
NBP liabilities and equity
NBP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
NBP balance sheet
| 2025 | 2024 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & short-term investments | $30.1M | $1.27B | $671.0M | $4.79B | $1.17B | $1.84B | $574.2M |
| Cash & equivalents | $30.1M | $498.2M | $552.8M | $4.76B | $1.14B | $1.59B | $307.9M |
| Short-term investments | $30,021 | $767.4M | $118.2M | $31.5M | $32.0M | $256.0M | $266.2M |
| Receivables | $256,327 | $8.6M | $61.0M | $357.9M | $55.3M | $9.4M | $4.1M |
| Inventory | $0 | $0 | $4.3M | $0 | −$55.9M | −$215.6M | $0 |
| Other current assets | $698,360 | $15.5M | $14.0M | $195.5M | $192.4M | $398.8M | $113.3M |
| Total current assets | $31.1M | $1.29B | $750.2M | $5.34B | $1.36B | $2.04B | $691.6M |
| Property, plant & equipment (net) | $421,589 | $27.7M | $24.9M | $40.3M | $46.5M | $27.7M | $22.3M |
| Goodwill & intangible assets | $0 | $0 | $44.3M | $283.0M | $311.4M | $311.4M | $311.4M |
| Long-term investments | $37.2M | $30.8M | $55.2M | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $204.1M | $4.2M | $666.8M | $18.3M | $0 | $0 |
| Total assets | $37.2M | $1.55B | $878.7M | $6.33B | $1.74B | $2.38B | $1.03B |
| Liabilities | |||||||
| Short-term debt | $127,377 | $6.0M | $4.8M | $8.1M | $56.8M | $80.0M | $99.0M |
| Deferred revenue | — | $773,672 | $371,660 | $9.9M | $3.9M | $14.2M | $2.4M |
| Total current liabilities | $3.8M | $61.7M | $97.9M | $576.1M | $588.5M | $346.2M | $195.1M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $3.1M | $3.9M | $17.6M | — | — | — | — |
| Other long-term liabilities | $384,133 | $22.4M | $65.5M | $136.1M | $3.18B | $2.98B | $1.13B |
| Total liabilities | $4.2M | $84.1M | $163.4M | $712.2M | $3.77B | $3.33B | $1.33B |
| Shareholders' equity | |||||||
| Common stock & paid-in capital | $3,859 | $138,677 | $19,767 | $114,000 | $6,000 | $6,000 | $6,000 |
| Retained earnings (deficit) | −$190.5M | −$9.39B | −$683.2M | −$2.02B | −$2.49B | −$1.01B | −$357.9M |
| Accumulated other comprehensive income | $5.9M | $243.7M | −$29.3M | −$50.8M | $70.1M | $59.4M | $5.7M |
| Total shareholders' equity | $33.0M | $1.47B | $715.3M | $5.63B | $1.07B | −$955.1M | $410.5M |
| Key figures | |||||||
| Total debt | $438,458 | $28.3M | $17.6M | $19.1M | $132.5M | $147.0M | $213.0M |
| Net cash (debt) | $29.7M | $1.24B | $653.3M | $4.77B | $1.04B | $1.70B | $361.2M |
| Working capital | $27.3M | $1.23B | $652.3M | $4.77B | $772.8M | $1.69B | $496.4M |
| Tangible book value | $33.0M | $1.47B | $671.0M | $5.34B | $758.1M | −$1.27B | $99.1M |
| Book value per share | $0.79 | $18.08 | $9.42 | $82.31 | $18.38 | −$16.42 | $7.06 |
| Shares outstanding | 41.6M | 81.2M | 76.0M | 68.4M | 58.2M | 58.2M | 58.2M |
| Current ratio | 8.09 | 20.90 | 7.66 | 9.28 | 2.31 | 5.88 | 3.54 |
| Quick ratio | 7.91 | 20.65 | 7.48 | 8.94 | 2.08 | 5.35 | 2.96 |
| Debt / equity | 0.01 | 0.02 | 0.02 | 0.00 | 0.12 | — | 0.52 |
| Equity / assets | 88.6% | 94.6% | 81.4% | 88.8% | 61.6% | −40.2% | 40.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $190.8M | $191.3M | $210.8M | $11.57B | $165.6M | $168.6M | $173.4M | $1.29B | $1.51B | $2.25B | $2.29B | $406.1M |
| Cash & equivalents | $190.6M | $191.1M | $210.6M | $11.56B | $165.4M | $53.6M | $68.3M | $556.6M | $1.10B | $2.25B | $2.14B | $325.3M |
| Short-term investments | $210,000 | $210,478 | $210,000 | $10.6M | $210,000 | $115.0M | $105.1M | $737.2M | $403.5M | $143.2M | $148.1M | $80.8M |
| Receivables | $5.6M | $256,327 | $0 | $6.6M | $2.0M | $4.6M | $0 | $0 | $0 | $1.8M | $0 | $14.1M |
| Inventory | $0 | $0 | $0 | $29.0M | $0 | $0 | $0 | $0 | $0 | $29.0M | $0 | $0 |
| Other current assets | $1.5M | $6.9M | $6.7M | $192.6M | $0 | $0 | $3.3M | $26.8M | $167.1M | $55.1M | $47.1M | $3.7M |
| Total current assets | $198.0M | $198.5M | $217.5M | $11.80B | $167.6M | $173.2M | $176.7M | $1.32B | $1.67B | $2.34B | $2.34B | $423.9M |
| Property, plant & equipment (net) | $5.6M | $5.6M | $2.9M | $22.5M | $3.4M | $3.6M | $3.8M | $25.9M | $28.2M | $82.9M | $82.9M | $14.1M |
| Goodwill & intangible assets | $0 | $0 | $0 | $118.1M | $0 | $0 | $0 | $0 | $0 | $118.1M | $118.1M | $38.7M |
| Long-term investments | $25.1M | $0 | $37.2M | $40.3M | $34.5M | $30.8M | $30.8M | $39.3M | $19.0M | $0 | $0 | $0 |
| Other non-current assets | $2.9M | $28.0M | $2.8M | $2.08B | $1.2M | $1.3M | $1.4M | $246.8M | $122.4M | $75.3M | $75.3M | $7.3M |
| Total assets | $231.5M | $232.1M | $260.5M | $14.06B | $206.7M | $208.9M | $212.7M | $1.63B | $1.84B | $2.61B | $2.61B | $484.1M |
| Liabilities | ||||||||||||
| Accounts payable | $4.6M | $4.7M | — | — | — | — | — | — | — | — | — | — |
| Short-term debt | $1.3M | $1.3M | — | $44.2M | $853,000 | $835,000 | — | $5.3M | $5.4M | $51.9M | $51.9M | $7.9M |
| Deferred revenue | — | — | — | $11.2M | — | $773,672 | — | — | — | $11.2M | — | $1.5M |
| Total current liabilities | $25.9M | $26.0M | $26.9M | $815.7M | $7.3M | $7.8M | $8.5M | $82.6M | $101.5M | $411.8M | $411.8M | $91.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $4.5M | — | $3.1M | $3.3M | $3.5M | $3.7M | $3.9M | $3.8M | $4.0M | — | — | — |
| Other long-term liabilities | $4.5M | $4.5M | $2.7M | $121.8M | $2.6M | $2.8M | $3.1M | $21.2M | $23.4M | $0 | $483.0M | $55.4M |
| Total liabilities | $30.4M | $30.5M | $29.6M | $937.5M | $10.0M | $10.6M | $11.5M | $103.8M | $124.9M | −$1.75B | $894.8M | $146.8M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $27,000 | $27,061 | — | $1.4M | $19,000 | $19,000 | — | $133,325 | $138,067 | $133,000 | $133,000 | $18,335 |
| Retained earnings (deficit) | −$1.37B | −$1.37B | −$1.33B | −$65.97B | −$1.29B | −$1.29B | −$1.29B | −$8.96B | −$9.13B | −$8.33B | −$8.33B | −$1.05B |
| Accumulated other comprehensive income | $42.0M | $42.1M | — | $2.17B | $37.0M | $33.4M | — | $293.8M | $293.9M | $1.75B | $298.3M | $51.9M |
| Total shareholders' equity | $201.1M | $201.6M | $230.9M | $13.12B | $196.7M | $198.3M | $201.2M | $1.53B | $1.72B | $1.75B | $1.72B | $337.3M |
| Key figures | ||||||||||||
| Total debt | $4.5M | $4.5M | — | $166.0M | $3.5M | $3.7M | — | $26.5M | $28.8M | $133.9M | $75.0M | $10.7M |
| Net cash (debt) | $186.4M | $186.8M | — | $11.41B | $162.1M | $164.9M | — | $1.27B | $1.48B | $2.12B | $2.21B | $395.4M |
| Working capital | $172.1M | $172.5M | $190.6M | $10.98B | $160.3M | $165.5M | $168.2M | $1.24B | $1.57B | $1.92B | $1.92B | $332.5M |
| Tangible book value | $201.1M | $201.6M | $230.9M | $13.01B | $196.7M | $198.3M | $201.2M | $1.53B | $1.72B | $1.63B | $1.60B | $298.6M |
| Book value per share | $1.74 | $1.74 | $0.87 | $299.01 | $2.41 | $2.43 | $1.07 | $18.76 | $21.25 | $21.66 | $20.63 | $4.06 |
| Shares outstanding | 115.7M | 115.7M | 265.4M | 43.9M | 81.7M | 81.6M | 187.5M | 81.5M | 80.9M | 80.9M | 83.3M | 83.2M |
| Current ratio | 7.64 | 7.64 | 8.09 | 14.47 | 22.82 | 22.35 | 20.90 | 15.99 | 16.50 | 5.67 | 5.67 | 4.64 |
| Quick ratio | 7.58 | 7.37 | 7.84 | 14.19 | 22.82 | 22.35 | 20.51 | 15.66 | 14.85 | 5.47 | 5.56 | 4.60 |
| Debt / equity | 0.02 | 0.02 | — | 0.01 | 0.02 | 0.02 | — | 0.02 | 0.02 | 0.08 | 0.04 | 0.03 |
| Equity / assets | 86.9% | 86.9% | 88.6% | 93.3% | 95.2% | 94.9% | 94.6% | 93.6% | 93.2% | 67.0% | 65.8% | 69.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed April 7, 2026); data from EODHD.
NBP financial position
At the end of fiscal 2025 (December 31, 2025), NovaBridge Biosciences had total assets of $37.2 million (down 97.6% from a year earlier), total liabilities of $4.2 million and shareholders' equity of $33.0 million. It held $30.1 million in cash and short-term investments against $0.4 million of debt, a net cash position of $29.7 million. Its current ratio was 8.09. In the latest quarter (ended June 30, 2026) total assets were $231.5 million and equity $201.1 million.
Related: NBP income statement, NBP cash flow statement, NBP key metrics. See the NBP stock overview for the latest quote and news.
NBP balance sheet FAQ
What are NovaBridge Biosciences's total assets?
NovaBridge Biosciences reported total assets of $37.2 million at the end of fiscal 2025 (December 31, 2025), compared with $1.6 billion a year earlier.
How much debt does NovaBridge Biosciences have?
NovaBridge Biosciences had $0.4 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.01.
How much cash does NovaBridge Biosciences have?
NovaBridge Biosciences held $30.1 million in cash and short-term investments at the end of fiscal 2025; with $0.4 million of debt that is net cash of $29.7 million.
What is NovaBridge Biosciences's book value?
NovaBridge Biosciences's shareholders' equity (book value) was $33.0 million at the end of fiscal 2025, or $0.79 per share.
What is NovaBridge Biosciences's current ratio?
NovaBridge Biosciences had current assets of $31.1 million and current liabilities of $3.8 million, a current ratio of 8.09 (it can cover its short-term obligations).